Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Finds “Comfort Level” With Using Medicare Data For Sentinel Initiative

Executive Summary

FDA research into the clinical accuracy and stability over time of Medicare claims data has shown it could be a reliable source of information for active product safety surveillance, according to FDA’s Judy Racoosin, scientific lead for the Sentinel Initiative within the Center for Drug Evaluation and Research.
Advertisement

Related Content

BI’s Pradaxa Gets Mixed Reviews In Postmarketing Studies
FDA’s Guidance Document To-Do List
FDA’s Guidance Document To-Do List
Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making
Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making
Sentinel Initiative's Potential Shortcomings Illuminated At Avandia Panel
Part D Drug Data Expected To Be Available For Research Dec. 1
Part D Drug Data Expected To Be Available For Research Dec. 1

Topics

Advertisement
UsernamePublicRestriction

Register

PS052693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel